RESEARCH TRIANGLE PARK, N.C., Feb. 24 /PRNewswire-FirstCall/ -- Paradigm
Genetics, Inc. (Nasdaq: PDGM), a biotechnology company, announced today that
Thomas J. Colatsky, Ph.D., Paradigm's Vice President of Healthcare Research,
would participate in a focus session entitled "Biomarkers: An Emerging and
Important Tool for Lessening Drug Development Risk," at the BIO CEO & Investor
Conference on Tuesday, February 24, 2004 at 3:30 PM ET in the Park Avenue
Suite North of the Waldorf-Astoria in New York.
About Paradigm Genetics
Paradigm Genetics is a biotechnology company applying a unique systems
biology approach to life sciences discovery. The Company is focused on the
discovery and validation of genes, targets and biomarkers for product
development in the pharmaceutical and agricultural industries, with an
internal focus on metabolic disorders, pathway engineering and chemical
genetics. The Company also provides value-added services in microarray
processing (Paradigm Array Labs(TM)), gene-based discovery
(GeneFunctionFactory(R)) and high throughput assay development. Paradigm
Genetics has five major customers: Bayer CropScience, Monsanto Company, the
National Institute of Environmental Health Sciences, the National Institute of
Standards & Technology's Advanced Technology Program and Pioneer Hi-Bred
International. For more information, visit http://www.paradigmgenetics.com .
This press release contains forward-looking statements, including
statements regarding the Company's expectations regarding business development
activities and near-term revenue opportunities; the financial statement impact
of the significant reduction in SG&A expense and increase in R&D investment;
and the Company's ability to hit its milestones and execute on its strategy.
Such forward-looking statements are based on management's current expectations
and are subject to a number of risks, factors and uncertainties that may cause
actual results, events and performance to differ materially from those
referred to in the forward-looking statements. These risks, factors and
uncertainties include, but are not limited to, Paradigm's early stage of
development, history of net losses, technological and product development
uncertainties, reliance on research collaborations, uncertainty of additional
funding and ability to protect its patents and proprietary rights. Certain of
these and other risks are identified in Paradigm's annual report on Form 10-K
for the year ended December 31, 2002 and in its quarterly report on Form 10-Q
for the quarter ended September 30, 2003, each filed with the Securities and
Exchange Commission. The Company does not intend to update any of the forward-
looking statements after the date of this release to conform these statements
to actual results or to changes in our expectations, except as may be required
by law.
SOURCE Paradigm Genetics, Inc.
 back to top
Related links:
http://www.paradigmgenetics.com
CONTACT:
Melissa Matson, Director, Corporate
Communications of Paradigm Genetics, Inc., +1-919-425-3000; or
Brian Ritchie or Mark Vincent of Euro RSCG Life NRP,
+1-212-845-4200
|
